MedTrace Logo

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

NCT06580106 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-02-02

No results posted yet for this study

Summary

The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

OTHER

Biospecimen samples

Buccal swabs and Blood samples will be collected throughout study.

Sponsors & Collaborators

  • Atrium Health Levine Cancer Institute

    collaborator OTHER

  • Swim Across America

    collaborator OTHER

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Brittany Ragon, MD · Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-09
Primary Completion
2027-07-31
Completion
2030-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06580106 on ClinicalTrials.gov